This BATI-NCORP program is designed to provide cancer patients, and healthy citizens ?at risk? for cancer, with opportunities to participate in NCI-sponsored clinical trials developed by the members of the National Clinical Trials Network (NCTN) and NCORP Research Bases. These clinical trials are intended to identify more effective and/or less toxic treatments for the prevention, detection, diagnosis, treatment, long-term supportive care, or end-of-life care for cancer patients. Via the BATI-NCORP, East Bay oncologists can provide their patients, at no cost, with opportunities to participate in the most advanced and promising forms of genetic therapy, immunotherapy, chemotherapy, surgery and radiation treatments.

Public Health Relevance

Since 2014, BATI has led the NCORP (NCI-Community Oncology Research Program) in the East Bay. This program conducts research in Cancer Care Delivery, Cancer Control and Prevention, and Cancer Therapeutics. BATI is the core member of this eight-member consortium of hospitals and private medical practices. It is responsible for all organizational, administrative and programmatic segments of the NCORP. BATI has the necessary financial, administrative and organizational strength to adapt to constant changes in the healthcare environment and the nation-wide evolution of community-based clinical research. The BATI-NCORP provides cancer patients, and healthy citizens ?at risk? for cancer with opportunities to participate in NCI-sponsored clinical trials designed by members of the National Clinical Trials Network (NCTN) and NCORP Research Bases. These clinical trials are designed to determine more effective and/or less toxic treatments for the prevention, detection, diagnosis, treatment, long-term supportive care, or end-of-life care for cancer patients. Via the BATI- NCORP, East Bay oncologists can provide their patients, at no cost, opportunities to participate in the most advanced and promising forms of genetic therapy, immunotherapy, chemotherapy, surgery and radiation treatments. Fifty-six percent of all patients in the BATI-NCORP are members of low income or historically underserved minority populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189817-07
Application #
9998857
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Bakos, Alexis Diane
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Bay Area Tumor Institute
Department
Type
DUNS #
040003402
City
Oakland
State
CA
Country
United States
Zip Code
94609
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69
Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9